Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals' stock has been impacted by several key events. The FDA granted accelerated approval for Rezdiffra in March 2024, and the drug was subsequently launched in the U.S. Madrigal reported robust Rezdiffra sales, with Q2 2025 net sales reaching $212.8 million and over 23,000 patients on the treatment as of June 30, 2025. Numerous research analysts have issued "Buy" or "Strong Buy" ratings for MDGL, with an average price target of $532.70. The company received a positive CHMP opinion recommending approval of Rezdiffra for MASH in Europe. Madrigal announced its Q2 2025 financial results on August 5, 2025, reporting higher-than-expected revenue and earnings per share. In the last ninety days, insiders acquired 165,683 shares valued at $61,921,142 and sold 248,642 shares valued at $91,388,103. Madrigal secured a new U.S. Rezdiffra patent extending protection to February 4, 2045, and announced a global licensing agreement for an oral GLP-1 development candidate. The stock has seen appreciation, with a robust 44% gain in nine months from January 2025 to October 2025.

The demand for Rezdiffra is driven by the prevalence and progression of MASH, a chronic and progressive liver disease. The total addressable market for MASH is significantly larger than the current patient base under treatment, with management identifying a potential market of 315,000 patients. As MASH disease awareness improves and prevalence increases, the number of diagnosed patients with moderate to advanced fibrosis is expected to grow, suggesting a consistent demand trend driven by medical need and market penetration. The strong and accelerating quarterly sales growth of Rezdiffra also indicates a steady increase in demand since its launch.

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH). Their primary product is Rezdiffra (resmetirom), the first FDA-approved medication for MASH with moderate to advanced liver fibrosis. The company also has small-molecule drugs in preclinical trial stages addressing cardiovascular and metabolic diseases.

Madrigal Pharmaceuticals is headquartered in West Conshohocken, Pennsylvania, United States. While its primary focus and FDA approval for Rezdiffra are in the U.S., the company has also received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for Rezdiffra in Europe, with a decision from the European Commission (EC) expected in August 2025, indicating a planned expansion into European markets.

Madrigal Pharmaceuticals' brand reputation has been significantly bolstered by the FDA approval of Rezdiffra in March 2024, making it the first approved treatment for MASH. The rapid U.S. launch and strong initial sales of Rezdiffra, along with positive analyst sentiment and European regulatory progress, further contribute to a strong brand reputation. The company is recognized for its innovative approach and therapeutic solutions within the biotechnology industry.

Institutional investors and hedge funds own a significant portion of Madrigal Pharmaceuticals' stock, with institutional holding reported at 102.44% of total shares held. Approximately 98.50% of the company's stock is owned by institutional investors and hedge funds. Company insiders own 21.50% of the stock. Major institutional owners include Bank of America Corp DE, BNP Paribas Financial Markets, Raymond James Financial Inc., Balyasny Asset Management L.P., and The Manufacturers Life Insurance Company.